TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

Funding News - Development and Application of PET and SPECT Imaging Ligands Encouraged

Archive folder iconHistorical Data

  • The information on this page is for historical and research purposes only.
  • For the most current NINDS funding announcements, please see the NINDS list of Active Funding Initiatives or Follow Us on Twitter for the latest funding news.

The National Institute of Neurological Disorders and Stroke (NINDS) encourages applications to develop and apply positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging ligands as biomarkers for drug discovery and for pathophysiological studies of central nervous system disorders. This announcement is made together with 5 other components of the National Institutes of Health (NIH) and is supported by 2 funding mechanisms: R21 and R33.

Tremendous opportunities exist for using PET and SPECT imaging in studies of the pathophysiology of brain disorders, but relatively few radioligands are currently available for functional imaging of target molecules implicated in normal brain function, aging, and brain and behavioral disorders. The purpose of this announcement is to support the development of novel radioligands for PET or SPECT imaging in the human brain.

For more information, potential applicants should contact Dr. Debra Babcock, Program Director, Systems and Cognitive Neuroscience Cluster, NINDS; telephone: 301-496-9964; e-mail: For a more detailed description of this announcement, visit (R21) or (R33).